Cargando…

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib

BACKGROUND: Transforming growth factor beta (TGF-β) signalling is involved in the development of hepatocellular carcinoma (HCC). We followed changes in biomarkers during treatment of patients with HCC with the TGF-βRI/ALK5 inhibitor galunisertib. METHODS: This phase 2 study (NCT01246986) enrolled se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giannelli, Gianluigi, Santoro, Armando, Kelley, Robin K., Gane, Ed, Paradis, Valerie, Cleverly, Ann, Smith, Claire, Estrem, Shawn T., Man, Michael, Wang, Shuaicheng, Lahn, Michael M., Raymond, Eric, Benhadji, Karim A., Faivre, Sandrine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094874/ https://www.ncbi.nlm.nih.gov/pubmed/32210440 http://dx.doi.org/10.1371/journal.pone.0222259

Ejemplares similares

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2021)

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Kelley, R.K., et al.
Publicado: (2019)

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
por: Herbertz, Stephan, et al.
Publicado: (2015)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
por: Wick, Antje, et al.
Publicado: (2020)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Publicado: (2020)

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients
por: Serova, Maria, et al.
Publicado: (2015)

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition
por: Schaer, David, et al.
Publicado: (2015)

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
por: Rodón, Jordi, et al.
Publicado: (2014)

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
por: Gueorguieva, Ivelina, et al.
Publicado: (2016)

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
por: Holmgaard, Rikke B., et al.
Publicado: (2018)

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2021)

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
por: Maier, Armin, et al.
Publicado: (2015)

A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2018)

NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC
por: Cao, Yuan, et al.
Publicado: (2017)

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer
por: Nadal, Ernest, et al.
Publicado: (2023)

Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression
por: Rani, Bhavna, et al.
Publicado: (2018)

Galunisertib Exerts Antifibrotic Effects on TGF-β-Induced Fibroproliferative Dermal Fibroblasts
por: Peterson, Joshua M., et al.
Publicado: (2022)

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
por: Yingling, Jonathan M., et al.
Publicado: (2017)

Therapeutic Effect of Polymeric Nanomicelles Formulation of LY2157299-Galunisertib on CCl(4)-Induced Liver Fibrosis in Rats
por: Panzarini, Elisa, et al.
Publicado: (2022)

Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro
por: Jank, Bernhard J., et al.
Publicado: (2022)

Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes
por: Zhang, Chao, et al.
Publicado: (2016)

Galunisertib enhances chimeric antigen receptor-modified T cell function
por: Wang, Zhixiong, et al.
Publicado: (2020)

The TGFβ type I receptor TGFβRI functions as an inhibitor of BMP signaling in cartilage
por: Wang, Weiguang, et al.
Publicado: (2019)

Galunisertib Drives Treg Fragility and Promotes Dendritic Cell-Mediated Immunity against Experimental Lymphoma
por: Hira, Sumit Kumar, et al.
Publicado: (2020)

Galunisertib-Loaded Gelatin Methacryloyl Hydrogel Microneedle Patch for Cardiac Repair after Myocardial Infarction
por: Chen, Haiting, et al.
Publicado: (2022)

Molecular characterization and expression of TGFβRI and TGFβRII and its association with litter size in Tibetan sheep
por: Zhang, Junxia, et al.
Publicado: (2023)

Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma
por: Zhang, Mengxian, et al.
Publicado: (2012)

Design of Gelatin-Capped Plasmonic-Diatomite Nanoparticles with Enhanced Galunisertib Loading Capacity for Drug Delivery Applications
por: Tramontano, Chiara, et al.
Publicado: (2021)

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
por: Kovacs, Richard J., et al.
Publicado: (2014)

Emdogain-Regulated Gene Expression in Palatal Fibroblasts Requires TGF-βRI Kinase Signaling
por: Stähli, Alexandra, et al.
Publicado: (2014)

Structure-Guide Design and Optimization of Potential Druglikeness Inhibitors for TGFβRI with the Pyrrolopyrimidine Scaffold
por: Meng, Dan, et al.
Publicado: (2022)

RI Lectures
Publicado: (1993)

Ri chu = Sunrise /
por: Cao, Yu, 1910-1996
Publicado: (2001)

SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade
por: Cashman, Rivki, et al.
Publicado: (2014)

Exon skipping of TGFβRI affects signalling and ECM expression in hypertrophic scar-derived fibroblasts
por: Raktoe, Rajiv S, et al.
Publicado: (2020)

Estradiol Ameliorates Acute Kidney Ischemia-Reperfusion Injury by Inhibiting the TGF-βRI-SMAD Pathway
por: Ren, Lian, et al.
Publicado: (2022)

The Interactivity between TGFβ and BMP Signaling in Organogenesis, Fibrosis, and Cancer
por: Dituri, Francesco, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0mm539ljh5jln1s3vhd44eqi0c